
Deirdre A Hill

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6460954/publications.pdf

Version: 2024-02-01



Πειρπρε Δ Ηιιι

#	Article	IF	CITATIONS
1	Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease. JAMA - Journal of the American Medical Association, 2003, 290, 465.	7.4	569
2	Mortality and Cancer Incidence Among Individuals With Down Syndrome. Archives of Internal Medicine, 2003, 163, 705.	3.8	200
3	Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood, 2008, 112, 5150-5160.	1.4	148
4	Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood, 2005, 106, 3358-3365.	1.4	101
5	Geographic Access to Breast Imaging for US Women. Journal of the American College of Radiology, 2014, 11, 874-882.	1.8	74
6	Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood, 2006, 108, 3161-3167.	1.4	73
7	Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics. Npj Breast Cancer, 2019, 5, 33.	5.2	73
8	Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. Breast Cancer Research and Treatment, 2016, 157, 545-554.	2.5	64
9	Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status. Cancer, 2016, 122, 611-617.	4.1	55
10	Is the closest facility the one actually used? An assessment of travel time estimation based on mammography facilities. International Journal of Health Geographics, 2016, 15, 8.	2.5	52
11	Underutilization of Supplemental Magnetic Resonance Imaging Screening Among Patients at High Breast Cancer Risk. Journal of Women's Health, 2018, 27, 748-754.	3.3	42
12	Travel Burden to Breast MRI and Utilization: Are Risk and Sociodemographics Related?. Journal of the American College of Radiology, 2016, 13, 611-619.	1.8	37
13	Breast cancer survival, survival disparities, and guideline-based treatment. Breast Cancer Research and Treatment, 2018, 170, 405-414.	2.5	34
14	Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1297-1304.	2.5	33
15	Long-term risk of medical conditions associated with breast cancer treatment. Breast Cancer Research and Treatment, 2014, 145, 233-243.	2.5	32
16	Multilevel factors associated with long-term adherence to screening mammography in older women in the U.S Preventive Medicine, 2016, 89, 169-177.	3.4	30
17	Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. JAMA Internal Medicine, 2018, 178, 458.	5.1	28
18	Utilization of breast cancer screening with magnetic resonance imaging in community practice. Journal of General Internal Medicine, 2018, 33, 275-283.	2.6	28

DEIRDRE A HILL

#	Article	IF	CITATIONS
19	Facility Mammography Volume in Relation to Breast Cancer Screening Outcomes. Journal of Medical Screening, 2016, 23, 31-37.	2.3	26
20	Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA. RNA Biology, 2020, 17, 1666-1673.	3.1	26
21	Knowledge and Uptake of Genetic Counseling and Colonoscopic Screening Among Individuals at Increased Risk for Lynch Syndrome and their Endoscopists from the Family Health Promotion Project. American Journal of Gastroenterology, 2016, 111, 285-293.	0.4	24
22	Alcohol, smoking, and risk of <scp>H</scp> er2â€overexpressing and tripleâ€negative breast cancer relative to estrogen receptorâ€positive breast cancer. International Journal of Cancer, 2018, 143, 1849-1857.	5.1	23
23	Method of Detection and Breast Cancer Survival Disparities in Hispanic Women. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2453-2460.	2.5	22
24	Efficacy of a Telehealth Intervention on Colonoscopy Uptake When Cost Is a Barrier: The Family CARE Cluster Randomized Controlled Trial. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1311-1318.	2.5	21
25	Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1802-1808.	2.5	20
26	Meningioma and schwannoma risk in adults in relation to family history of cancer. Neuro-Oncology, 2004, 6, 274-280.	1.2	18
27	Social-group identity and population substructure in admixed populations in New Mexico and Latin America. PLoS ONE, 2017, 12, e0185503.	2.5	18
28	Estrogen receptor quantitative measures and breast cancer survival. Breast Cancer Research and Treatment, 2017, 166, 855-864.	2.5	17
29	Temporal trends in breast cancer survival by race and ethnicity: A population-based cohort study. PLoS ONE, 2019, 14, e0224064.	2.5	16
30	Cancer in first-degree relatives and risk of glioma in adults. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 1443-8.	2.5	16
31	Relationship between Insurance Type at Diagnosis and Hepatocellular Carcinoma Survival. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 300-307.	2.5	15
32	Spreading depolarization may represent a novel mechanism for delayed fluctuating neurological deficit after chronic subdural hematoma evacuation. Journal of Neurosurgery, 2020, 134, 1-9.	1.6	14
33	Availability of Advanced Breast Imaging at Screening Facilities Serving Vulnerable Populations. Journal of Medical Screening, 2016, 23, 24-30.	2.3	13
34	Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer. Hormones and Cancer, 2019, 10, 71-76.	4.9	9
35	Advanced Breast Imaging Availability by Screening Facility Characteristics. Academic Radiology, 2015, 22, 846-852.	2.5	7
36	A novel cytokine profile associated with cancer metastasis to mediastinal and hilar lymph nodes identified using fine needle aspiration biopsy – A pilot study. Cytokine, 2017, 89, 98-104.	3.2	6

DEIRDRE A HILL

#	Article	IF	CITATIONS
37	Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer. Cancer Causes and Control, 2021, 32, 1375-1384.	1.8	3
38	NHL and genomic variability in RAG1 and BRCA2. Blood, 2007, 109, 5523-5523.	1.4	0
39	Strengthening Gynecologic Cancer Prevention Studies. Obstetrics and Gynecology Clinics of North America, 2007, 34, 639-650.	1.9	0